All In Biotech

Drug Trial Radar · NCT03459079

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Actual

Start

Aug 14, 2018

Primary completion

Apr 18, 2023

Study completion Jun 1, 2023

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Inventiva Pharma
First posted
Mar 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Specifically, to determine if lanifibranor decreases intrahepatic triglycerides (IHTG) (primary endpoint), improves hepatic insulin sensitivity, endogenous (hepatic) glucose production, de novo lipogenesis (DNL), HbA1c and lipid profiles. In addition, exploratory analysis with surrogate plasma biomarkers and imaging on liver fibrosis changes on with treatment will be performed.

Conditions

  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Type 2 Diabetes (T2DM)

Interventions

  • LanifibranorDrug

    The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day

  • PlaceboOther

    Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Intrahepatic Triglycerides (IHTG) Quantified by Proton Magnetic Resonance and Spectroscopy (¹H-MRS)Time frame: 24 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.